Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation

Korean Journal of Hematology

Volumn 46, Issue 1, 2011, Pages 18-23

  Goh, Ri Young ^a   Kim, Sung Hyun ^a   Han, Jin Yeong ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

Lineage specific chimerism; Myeloablative stem cell transplantation; Natural killer cells; T cells

Indexed keywords

EID: 84859141635     PISSN: 17387949     EISSN: 20929129     Source Type: Journal    
DOI: 10.5045/kjh.2011.46.1.18     Document Type: Article

References (29)

1. Lion T. Detection of impending graft rejection and relapse by lineage-specific chimerism analysis. Methods Mol Med 2007;134: 197-216.
2. Bader P, Kreyenberg H. Analysis of chimerism after stem cell transplantation. Methods Mol Med 2004;91:247-64.
3. Liesveld JL, Rothberg PG. Mixed chimerism in SCT: conflict or peaceful coexistence? Bone Marrow Transplant 2008;42:297-310.
4. Khan F, Agarwal A, Agrawal S. Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Transplant 2004;34:1-12.
5. Gineikiene E, Stoskus M, Griskevicius L. Recent advances in quantitative chimerism analysis. Expert Rev Mol Diagn 2009;9: 817-32.
6. + peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica 2009;94:1613-7.
7. Kristt D, Stein J, Yaniv I, Klein T. Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility. Bone Marrow Transplant 2007;39:255-68.
8. Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005;35:107-19.
9. Ma X, Wu D, Sun A, et al. The value of monitoring minimal residual disease in the patients with donor lymphocyte infusion as intervention of relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2010;85:141-2.
10. Dey BR, Shaffer J, Yee AJ, et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant 2007;40:19-27.
11. Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006;20:1690-700.
12. Dey BR, McAfee S, Colby C, et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003;9:320-9.
13. Kristt D, Israeli M, Narinski R, et al. Hematopoietic chimerism monitoring based on STRs: quantitative platform performance on sequential samples. J Biomol Tech 2005;16:380-91.
14. Thiede C. Diagnostic chimerism analysis after allogeneic stem cell transplantation: new methods and markers. Am J Pharmacogenomics 2004;4:177-87.
15. Lobashevsky AL, Senkbeil RW, Townsend JE, Mink CA, Thomas JM. Quantitative analysis of chimerism using a short tandem repeat method on a fluorescent automated DNA sequencer. Clin Lab Haematol 2006;28:40-9.
16. Horn B, Soni S, Khan S, et al. Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. Bone Marrow Transplant 2009;43: 469-76.
17. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004;104:2254-62.
18. Zeiser R, Spyridonidis A, Wäsch R, et al. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia 2005;19:814-21.
19. Huisman C, de Weger RA, de Vries L, Tilanus MG, Verdonck LF. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant 2007;39:285-91.
20. + selected cells from peripheral blood. Leukemia 2003;17:613-20.
21. Schaap N, Schattenberg A, Mensink E, et al. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation. Leukemia 2002;16:13-21.
22. Choi SJ, Lee KH, Lee JH, et al. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 2000;26:327-32.
23. Goh RY, Cho SS, Song YJ, et al. Clinical utility of chimerism status assessed by lineage-specific short tandem repeat analysis: experience from four cases of allogeneic stem cell transplantation. Korean J Lab Med 2009;29:277-81.
24. Lion T, Daxberger H, Dubovsky J, et al. Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 2001;15:307-10.
25. Clausen J, Kircher B, Auberger J, et al. The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. Biol Blood Marrow Transplant 2010;16:273-80.
26. Campregher PV, Gooley T, Scott BL, et al. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2007;40:965-71.
27. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.
28. Michallet AS, Fürst S, Le QH, et al. Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens. Br J Haematol 2005;128:676-89.
29. Mattsson J, Uzunel M, Brune M, et al. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2001;115:935-44.